Find clinical trials for Acute Myeloid Leukemia (AML) in Nashville, TN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near Nashville, TN, USA:
(R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease....
Phase 1
Nashville, Tennessee, United States and 2 other locations
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (...
Phase 1
Nashville, Tennessee, United States and 8 other locations
The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML...
Phase 1
Nashville, Tennessee, United States and 16 other locations
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML...
Phase 1
Nashville, Tennessee, United States and 43 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Nashville, Tennessee, United States and 85 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Nashville, Tennessee, United States and 160 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Nashville, Tennessee, United States and 43 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Nashville, Tennessee, United States and 55 other locations
in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...
Phase 1, Phase 2
Nashville, Tennessee, United States and 33 other locations
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...
Phase 1
Nashville, Tennessee, United States and 36 other locations
Clinical trials
Research sites
Resources
Legal